Breaking News

ERT Reaches Data Milestone

By Kristin Brooks | January 8, 2014

Supports more than 300 successful NDAs

ERT has reached a milestone in data capture supporting the approval of new medical products. To date, global regulatory agencies have issued more than 300 approvals to biopharma companies that utilized ERT’s cardiac safety, respiratory, or eCOA solutions to capture safety and/or efficacy data in their clinical programs. ERT’s products and services for cardiac safety, respiratory, and eCOA include electronic patient reported outcomes (ePRO).
 
“It is extremely rewarding to realize that so many biopharmaceutical companies have brought new medical treatments to market using products and services delivered by ERT,” said Jeffrey Litwin, M.D., chief executive officer of ERT. “We are committed to delivering innovative and reliable solutions that meet the needs of our worldwide customers and supporting their efforts to bring life-enhancing and life-saving medical products to patients who need them.”

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research